Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Gilead Sciences Inc GILD

Healthcare Drug Manufacturers - Major
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GILD)

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Business Wire 3 hours ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Business Wire 2 days ago

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Business Wire 2 days ago

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

Business Wire 2 days ago

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Business Wire November 24, 2025

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

PR Newswire November 20, 2025

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Business Wire November 18, 2025

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Business Wire November 13, 2025

Gilead Provides Update on Phase 3 ASCENT-07 Study

Business Wire November 7, 2025
View More News ››

Opinion & Analysis (NDAQ:GILD)

Gilead, Teva, XPhyto - Global marketing potential

Stockhouse Editorial June 16, 2020

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

Stockhouse Editorial April 24, 2020

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

Stockhouse Editorial March 19, 2020

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Streetwise Reports July 16, 2019

With acquisition of Kite Pharma, Gilead becomes a 'major player' in CAR-T arena

The Life Sciences Report August 30, 2017

HIV vaccine clinical study results in high immune response rates in healthy subjects

The Life Sciences Report June 2, 2017
View More Opinion ››

Bullboard Posts (NDAQ:GILD)

Kevin Harrington Speaks about FSD Pharma

FSD Pharma Inc is about to launch this breakthrough product!!<< View Post To Watch Video >>
Peng26 - April 13, 2023

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Rebecca - April 13, 2023

roughly $80 billion biopharmaceutical company

The wide array of offerings helps fuel consistent payouts to shareholders. Current distributions are 73 cents per quarter, up 70% from 43...
jonathanS - August 3, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

 
Rebecca - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >>
Rebecca - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

Rebecca - June 1, 2022
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp., an exploration stage company, acquires, explores, and develops natural resource properties ...
View More »